Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Primary Myelofibrosis 4Anemia 4Leukemia, Myeloid, Acute 2beta-Thalassemia 1Thrombocytosis 1Higher-risk Myelodysplastic Syndrome 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 21fludarabine 20fludarabine phosphate 17Tacrolimus 12thymoglobulin 11Whole-Body Irradiation 11Busulfan 10Azacitidine 10Mycophenolic Acid 9Methotrexate 9Thiotepa 8Melphalan 8Antilymphocyte Serum 8venetoclax 7AP 1903 reagent 7Rituximab 6Sirolimus 5Imatinib Mesylate 5Granulocyte Colony-Stimulating Factor 5Cytarabine 5Cord Blood Stem Cell Transplantation 5merphos 4aldesleukin 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Interleukin-2 4Dexamethasone 4enasidenib 3Tretinoin 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × luspatercept × Myeloid × Clear all
NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
196 enrolled
MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡